ORYZON’s iadademstat shows efficacy signs in relapsed SCLC
2019-09-09 · Oryzon Genomics S.A. · original oryzon.com ↗
9 September 2019 MADRID, SPAIN and CAMBRIDGE MA. • Preliminary data from CLEPSIDRA Phase II trial presented at WCLC 2019 • Case study showing a 86% tumor reduction • Additional data will be presented late September at ESMO-2019 Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today presents the first preliminary data from CLEPSIDRA, a Phase II trial investigating iadademstat in combination with standard-of-care in relapsing small cell lung cancer (SCLC) patients. Click here to see the full Press Release
The release as fetched from its publisher. oryzon.com ↗